Banka BioLoo Limited has informed the Exchange regarding Board meeting held on February 12, 2026.
BANKA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Banka BioLoo's board, meeting on Feb 12, 2026, approved unaudited financial results for Q3 and 9M ended Dec 31, 2025, with a clean limited review report from auditor B.D. Saboo & Associates. On a standalone basis, revenue from operations for the quarter rose to Rs. 1,592.80 lakhs from Rs. 1,418.82 lakhs in Q3 FY25 (about 12% YoY growth), while 9M revenue was Rs. 4,173.48 lakhs vs Rs. 4,091.59 lakhs (roughly 2% YoY). The company reported a standalone loss after tax of Rs. 22.01 lakhs in Q3 and Rs. 118.85 lakhs for 9M FY26, an improvement from the Rs. 756.74 lakh loss a year ago, which had included exceptional items of Rs. 712.27 lakhs. On a consolidated basis, Q3 revenue was Rs. 1,526.49 lakhs with a loss after tax of Rs. 12.45 lakhs, and 9M loss was Rs. 121.09 lakhs. EPS stood at (Rs. 0.20) standalone and (Rs. 0.14) consolidated for the quarter.
Quarterly revenue growth is encouraging, but the company remains loss-making, with improving margins as prior-year exceptional charges drop out. Shareholders may see this as a sign of operating recovery, though bottom-line profitability has not yet been achieved.